Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.

  • Revenue in USD (TTM)44.04bn
  • Net income in USD-1.25bn
  • Incorporated1992
  • Employees83.10k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AZN:LSE since
announced
Transaction
value
TeneoTwo IncDeal completed05 Jul 202205 Jul 2022Deal completed1.79%1.27bn
Data delayed at least 20 minutes, as of Aug 17 2022 16:45 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Amgen, Inc.26.38bn6.58bn132.86bn24.20k21.3655.7413.565.1111.8011.8047.504.520.44321.485.381,090,248.0011.0511.0714.3213.4075.7579.2924.9230.881.177.460.937949.282.182.47-18.87-5.261.0111.97
Bristol-Myers Squibb Co47.14bn6.62bn160.06bn32.20k24.884.909.343.393.013.0121.4915.270.44654.586.001,464,099.006.292.677.763.2979.2274.1814.086.541.345.550.5629163.849.0919.01177.589.43-4.355.22
AstraZeneca plc (ADR)44.04bn-1.25bn202.87bn83.10k--5.7231.654.60-0.425-0.42514.2811.590.51742.025.77529,939.80-1.472.62-1.983.6674.8578.90-2.846.610.67375.850.451196.2640.5810.22-96.50-49.76-1.01--
Merck & Co., Inc.57.17bn16.64bn226.78bn68.00k13.605.2211.133.956.566.5322.5317.070.57813.036.54840,720.6016.847.6121.8310.1470.7770.9229.1316.061.1521.890.422386.0617.314.12173.1825.7922.487.49
AbbVie Inc57.35bn12.57bn247.98bn50.00k19.9317.0111.924.357.077.0732.278.290.39394.955.421,146,980.008.697.4611.109.4670.7272.0322.0518.110.74568.270.832497.8922.6916.99151.7114.1310.4417.93
Pfizer Inc.101.13bn29.75bn279.31bn79.00k9.63--8.142.775.195.1117.62--------1,280,152.00--6.62--8.2562.2174.0429.4421.32--22.12--75.7295.169.00238.0525.516.285.39
Eli Lilly And Co29.07bn5.69bn287.92bn35.00k48.6133.8739.639.966.276.2732.028.990.61281.814.77830,591.4012.0011.0817.8315.8075.9877.1619.5820.770.8467.330.660153.7515.405.94-9.8815.3111.4010.76
Data as of Aug 17 2022. Currency figures normalised to AstraZeneca PLC's reporting currency: US Dollar USD

Institutional shareholders

10.24%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 202294.23m3.04%
Wellington Management Co. LLPas of 31 Mar 202246.69m1.51%
PRIMECAP Management Co.as of 30 Jun 202245.81m1.48%
Capital Research & Management Co. (International Investors)as of 31 Mar 202236.99m1.19%
Fisher Asset Management LLCas of 30 Jun 202221.39m0.69%
Fidelity Management & Research Co. LLCas of 30 Jun 202218.92m0.61%
GQG Partners LLCas of 31 Mar 202218.28m0.59%
Franklin Advisers, Inc.as of 30 Jun 202214.85m0.48%
CIBC Private Wealth Advisors, Inc.as of 30 Jun 202210.73m0.35%
Norges Bank Investment Managementas of 31 Dec 20219.31m0.30%
More ▼
Data from 31 Dec 2021 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.